Podcasts and Transcripts
In this section, listen to podcasts and download transcripts from past events for women diagnosed with triple-negative breast cancer.
After treatment, you may experience your body and your interest in sex differently.
This program will help women affected by breast cancer manage their complex feelings at the holidays.
Because there are no targeted therapies for triple-negative breast cancer after initial treatment ends, you may seek other ways to manage your fears and reduce your risk for recurrence.
Connecting to an inner peace or to a higher power can instill a sense of support and strength during life’s big challenges
Learn the latest in cancer research and treatment from the annual meeting of the American Society of Clinical Oncology.
Learn about today’s standard of care for breast cancer that tests negative for estrogen, progesterone and HER2 receptors.
Learn about triple-negative breast cancer in young women, medical updates, treatment options and post-treatment follow-up care.
Learn about what lifestyle and dietary changes you can make to lower risk of recurrence.
Learn about this diagnosis of breast cancer that tests negative for the estrogen, progesterone, and HER2 receptors.
Understand the specific treatments used to manage metastasis in women whose cancer tests negative for the estrogen, progesterone and HER2 receptors. Learn about standard of care treatments, pipeline research and ways you can influence research moving forward.
Learn about the latest medical updates on triple-negative breast cancer.
Learn about recent advances in neoadjuvant and adjuvant treatment for early-stage breast cancer.
Learn about this form of breast cancer that tests negative for estrogen, progesterone and HER2/neu receptors.
Get updates from the largest annual meeting of cancer doctors in the world.
Explore your unique and complex feelings after treatment ends for triple-negative breast cancer
Hear medical updates and treatment news specific to a diagnosis of triple-negative breast cancer.
Take a closer look at triple-negative breast cancer, cancer that tests negative for the estrogen and progesterone receptor and HER2/neu protein and is more prevalent among young women.
Learn about the latest findings from the annual meeting of the American Society of Clinical Oncology.
Learn about available treatment options for triple-negative breast cancer, how you may be able to reduce your risk of recurrence and how to create a follow-up care plan that addresses your individual needs.
Get the latest news on triple-negative breast cancer from medical and nutrition experts. Learn the basics of triple-negative breast cancer and treatments, and learn how nutrition may influence risk of recurrence.
Hear the top news from the 2010 annual meeting of the American Society of Clinical Oncology. Learn about the latest research for hormone receptor-positive, HER2-positive and triple-negative breast cancers. Get updates on long-term post-treatment concerns.
Get the emerging news on research for metastatic triple-negative breast cancer, or breast cancer that tests negative for estrogen, progesterone and HER2. Learn about standard treatments; cutting-edge therapies; and ways to manage common symptoms and treatment side effects.
Understand the latest research and treatment options for early-stage and metastatic triple-negative breast cancer. Explore the latest findings on triple-negative breast cancer risk factors including gene mutation, age and race and ethnicity.
Learn more about triple-negative breast cancer; its causes and treatments; and the most promising new research. This program features information for premenopausal women, who are more likely than women in other age groups to be diagnosed with triple-negative breast cancer.
Learn why some groups of people are more likely to be diagnosed with triple-negative breast cancer and why. Dr. Swaby discusses available treatment options including a review of the latest research in targeted and biological therapies, how to manage follow-up care and the importance of participating in clinical trials to further research development.